BR112021023110A2 - Métodos de tratamento de síndrome de sjögren com o uso de um inibidor de tirosina quinase de bruton - Google Patents

Métodos de tratamento de síndrome de sjögren com o uso de um inibidor de tirosina quinase de bruton

Info

Publication number
BR112021023110A2
BR112021023110A2 BR112021023110A BR112021023110A BR112021023110A2 BR 112021023110 A2 BR112021023110 A2 BR 112021023110A2 BR 112021023110 A BR112021023110 A BR 112021023110A BR 112021023110 A BR112021023110 A BR 112021023110A BR 112021023110 A2 BR112021023110 A2 BR 112021023110A2
Authority
BR
Brazil
Prior art keywords
syndrome
methods
tyrosine kinase
kinase inhibitor
treating
Prior art date
Application number
BR112021023110A
Other languages
English (en)
Inventor
Vitaliti Garami Alessandra
Andrijana Radivojevic
Arvind Kinhikar
Bruno Bieth
Bruno Cenni
Maciej Cabanski
Martin Kaul
Souvik Bhattacharya
De Buck Stefan
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112021023110A2 publication Critical patent/BR112021023110A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

método de tratamento de síndrome de sjorgren com o uso de um inibidor de tirosina quinase de bruton. a presente invenção refere-se a métodos para tratamento da doença da síndrome de sjögren com o uso de um composto da fórmula (i) ou um sal farmaceuticamente aceitável do mesmo. também é revelado no presente documento um composto da fórmula (i) ou um sal farmaceuticamente aceitável do mesmo, para tratar pacientes com síndrome de sjögren, assim como medicamentos, regimes de dosagem, formulações farmacêuticas, formas de dosagem e kits para uso nos usos e métodos revelados.
BR112021023110A 2019-05-23 2020-05-20 Métodos de tratamento de síndrome de sjögren com o uso de um inibidor de tirosina quinase de bruton BR112021023110A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962851994P 2019-05-23 2019-05-23
PCT/IB2020/054754 WO2020234781A1 (en) 2019-05-23 2020-05-20 Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor

Publications (1)

Publication Number Publication Date
BR112021023110A2 true BR112021023110A2 (pt) 2022-04-12

Family

ID=70918750

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021023110A BR112021023110A2 (pt) 2019-05-23 2020-05-20 Métodos de tratamento de síndrome de sjögren com o uso de um inibidor de tirosina quinase de bruton

Country Status (13)

Country Link
US (1) US20220175772A1 (pt)
EP (1) EP3972603A1 (pt)
JP (1) JP2022533968A (pt)
KR (1) KR20220011652A (pt)
CN (1) CN113811301A (pt)
AU (1) AU2020278236A1 (pt)
BR (1) BR112021023110A2 (pt)
CA (1) CA3137271A1 (pt)
CL (1) CL2021003034A1 (pt)
IL (1) IL287745A (pt)
MX (1) MX2021014161A (pt)
TW (1) TW202110451A (pt)
WO (1) WO2020234781A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7443543B2 (ja) 2021-01-26 2024-03-05 ノバルティス アーゲー 医薬組成物
KR20240055038A (ko) 2021-09-03 2024-04-26 노파르티스 아게 다발성 경화증 치료를 위한 lou064
JP2024504267A (ja) 2021-12-14 2024-01-31 ノバルティス アーゲー Ｌｏｕ０６４を使用した治療の方法
TW202342048A (zh) 2022-02-28 2023-11-01 瑞士商諾華公司 使用ｌｏｕ０６４治療化膿性汗腺炎之方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
KR20180095655A (ko) * 2015-12-16 2018-08-27 베링거 인겔하임 인터내셔날 게엠베하 자가 면역 질환의 치료에 유용한 비피라졸릴 유도체
JP6916185B2 (ja) * 2016-01-13 2021-08-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｔｋ阻害剤としてのイソキノロン類
AR113796A1 (es) * 2017-11-06 2020-06-10 Lilly Co Eli Compuestos inhibidores de tirosina cinasa de bruton (btk)

Also Published As

Publication number Publication date
AU2020278236A1 (en) 2022-01-06
IL287745A (en) 2021-12-01
JP2022533968A (ja) 2022-07-27
TW202110451A (zh) 2021-03-16
MX2021014161A (es) 2022-01-04
AU2020278236A8 (en) 2022-04-28
CA3137271A1 (en) 2020-11-26
EP3972603A1 (en) 2022-03-30
KR20220011652A (ko) 2022-01-28
US20220175772A1 (en) 2022-06-09
WO2020234781A1 (en) 2020-11-26
CN113811301A (zh) 2021-12-17
CL2021003034A1 (es) 2022-09-09

Similar Documents

Publication Publication Date Title
BR112021023110A2 (pt) Métodos de tratamento de síndrome de sjögren com o uso de um inibidor de tirosina quinase de bruton
Colla et al. Serotonergic and noradrenergic systems are implicated in the antidepressant-like effect of ursolic acid in mice
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
BR112015029512A8 (pt) derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas
EA202092154A1 (ru) Комбинированная терапия
BR112014028633A8 (pt) tratamento de amd usando sflt-1 de aav
GT200800256A (es) Derivados de pirazolo [3,4-d]-pirimidina útiles para tratar trastornos respiratorios
BR112021022602A2 (pt) Métodos para tratamento de urticária espontânea crônica com o uso de um inibidor de tirosina quinase de bruton
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
ECSP109935A (es) Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
US20140147415A1 (en) Treatment of mastocytosis with masitinib
ATE485037T1 (de) Krebsbehandlung mittels fts und 2-deoxyglucose
BR112014017985A8 (pt) Combinação de um inibidor de rtk com um antiestrogênio e uso da mesma para o tratamento de cancer
BR112021024380A2 (pt) Formulações de liberação modificadas e usos das mesmas
BR112021025764A2 (pt) Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo
BR112021021826A8 (pt) Uso de apremilaste e um inibidor da tirosina quinase 2 no tratamento de uma doença ou um transtorno responsivo à inibição da fosfodiesterase tipo 4
BR112022000382A2 (pt) Administração de agonista de sting e inibidores de checkpoint
UY31417A1 (es) Una composicion farmacéutica y un proceso para dicha composicion farmacéutica
PE20211818A1 (es) Composicion farmaceutica para administracion oral que comprende derivado de aminopirimidina o su sal
BR112022008000A2 (pt) Derivado de pirazol-heteroarila, método de preparação para o mesmo e uso médico do mesmo
BR112021014854A2 (pt) Tratamento de lesões de pele e prurido em pacientes com prurigo nodularisis
BR112021011325A2 (pt) Derivados de rapamicina
Leclerc et al. The NEDD8-activating enzyme inhibitor pevonedistat activates the eIF2α and mTOR pathways inducing UPR-mediated cell death in acute lymphoblastic leukemia
BR112012020377A8 (pt) utilização de um ou mais selecionado do grupo constituído por um composto da fórmula (i), uma mistura racêmica-diastereomérica e um isômero óptico do referido composto, e um sal farmaceuticamente aceitável e uma pródroga do mesmo, método, composição farmacêutica e kit para tratamento de caquexia e embalagem comercial